Nausea is the most commonly reported side effect of GLP-1 medications. Whether you’re taking Ozempic, Wegovy, Saxenda, or Mounjaro, an upset stomach during the first few weeks of treatment is a common experience for many people. In this article, you’ll learn why this happens, how long it might last, and what changes to your diet and habits can make a difference.
Why does GLP-1 medication cause nausea?
GLP-1 agonists work by activating GLP-1 receptors in the gastrointestinal tract and the brain. One of the effects is that it slows down gastric emptying: food stays in the stomach longer, making you feel full faster and eat less. This delay is beneficial for weight loss, but at the same time, it’s the direct cause of nausea, bloating, and sometimes vomiting. The body interprets the delayed gastric emptying as a signal that something is wrong, especially in the beginning when it is not yet accustomed to the drug’s effects.
The STEP 1 study showed that nausea occurred in over 44% of participants taking semaglutide 2.4 mg. The good news: clinical research shows that only 4.5% discontinued treatment due to gastrointestinal symptoms. For most people, the symptoms are mild to moderate and clearly decrease as treatment continues.
When is the nausea at its worst?
Nausea usually occurs in the first few days to weeks after a dose increase. With semaglutide and tirzepatide, which are injected weekly, the day after the injection may be slightly more difficult. With liraglutide (Saxenda), which is taken daily, the pattern is continuous but people also get used to it more quickly. As the dose stabilizes and the body gets used to the medication’s effects, nausea decreases significantly for most people.
The titration schedule for GLP-1 medication is designed with slow steps for a reason. By gradually increasing the dose, the body has time to adjust. Read more about how this works on the Wegovy page on Goodweigh. If you still experience persistent symptoms, discuss with your healthcare provider whether a longer interim step is advisable.
What can you eat to reduce nausea?
Diet has a major impact on how you feel during treatment. Fatty, heavy, or heavily spiced meals further delay stomach emptying, which increases the likelihood of nausea. Small, light meals spread throughout the day work better than three large portions. Eat slowly, chew thoroughly, and stop when you’re full, even if the portion is smaller than you’re used to.
An expert consensus statement from international specialists emphasizes that practical dietary and lifestyle adjustments can significantly reduce nausea associated with GLP-1 medication. Specifically, it helps to choose foods that are easy to digest: steamed vegetables, rice, soup, and cooked meat. Avoid carbonated drinks, alcohol, and fast-acting sugars during the first few weeks of treatment or immediately after a dose increase. You can find more information about what works well with GLP-1 use in the article on what to eat when using GLP-1 medication.
When should you contact your doctor?
Mild nausea is a normal and expected part of treatment. However, there are situations in which you should contact a doctor. This applies if you are so nauseous that you can no longer eat or drink, if vomiting persists for several days, if you experience signs of dehydration such as a dry mouth, infrequent urination, or dizziness, or if you have severe abdominal pain in the upper abdomen or back. The latter could be a sign of acute pancreatitis, a rare but serious side effect that can occur with all GLP-1 medications.
A recent review of nausea as a side effect of GLP-1 medication confirms that side effects are generally manageable for most users and decrease over the course of treatment, but that medical supervision remains essential for more severe symptoms. At Goodweigh, you always have access to your treating physician if side effects occur.
Does nausea vary by medication?
All GLP-1 medications have a similar side effect profile regarding the stomach and intestines, but there are subtle differences. Liraglutide (Saxenda) has a shorter half-life and is injected daily, which means you get used to it faster but also experience a new injection peak every day. Semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) are injected weekly and have a longer half-life, resulting in a more consistent effect but a slightly more noticeable transition when the dose is increased.
In addition to the GLP-1 receptor, tirzepatide also activates the GIP receptor. In the SURMOUNT trials, tirzepatide had a similar GI profile to semaglutide with comparable weight loss, with nausea and diarrhea being the most common side effects. For an overview of all available medications, visit the weight loss medications page on Goodweigh.
Nausea as a sign, not a reason to stop
Nausea with GLP-1 medication is unpleasant, but it’s also a sign that the medication is working. The body is adapting to a new way of processing food. For most people, it subsides over the course of weeks, especially if the dose remains stable. Don’t let the first few weeks discourage you: the likelihood of significant weight loss has been demonstrated, and the side effects are temporary for most people.
If you’re unsure whether treatment with GLP-1 medication is right for you, or if you want to know if you’re eligible, read the overview article on when you’re eligible for GLP-1 medication. You can also start an intake directly with Goodweigh, where the doctor will assess your situation and create a personalized treatment plan.
References
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
- Ghusn, W., & Hurtado, M. D. (2024). Glucagon-like receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obesity Pillars, 10, 100127. https://doi.org/10.1016/j.obpill.2024.100127
- Sievenpiper, J. L., Ard, J., Blüher, M., et al. (2025). Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: An expert consensus statement using a modified Delphi approach. Obesity Pillars, 14, 100228. https://doi.org/10.1016/j.obpill.2025.100228
Your Final Weight Loss Program
Transform your life with our personalized telehealth weight loss program designed for lasting success.
.avif)
